AstraZeneca's MedImmune unit has licensed a cancer vaccine from Inovio for potential use with some of its immunotherapy drug candidates in yet another deal in the immune-oncology (IO) space.
MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, which it intends to study in combination with selected immunotherapy molecules within its own pipeline for HPV-driven cancers. MedImmune is paying Inovio $27.5m up front, plus development and commercial milestones that could reach $700m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?